HIGH-DOSE CHEMORADIOTHERAPY FOLLOWED BY RESCUE WITH MOBILIZED AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH LOW-GRADE, TRANSFORMED, OR FOLLICULAR LARGE CELL NON-HODGKIN'S LYMPHOMA
OBJECTIVES: I. Evaluate the overall and progression-free survival of patients with selected
poor-prognosis non-Hodgkin's lymphomas treated with high-dose etoposide and total-body
irradiation followed by rescue with peripheral blood stem cells. II. Determine the toxicity
of this regimen. III. Evaluate the short-term and long-term engraftment characteristics of
patients treated on this regimen.
OUTLINE: Patients who respond on Regimen A and who have no bulk disease greater than 5 cm
are treated on Regimen B. Regimen A: Single-Agent Chemotherapy/Stem Cell Mobilization with
Urothelial Protection and Growth Factor Therapy. Cyclophosphamide, CTX, NSC-26271; with
Mesna, NSC-113891; and Granulocyte Colony Stimulating Factor (Amgen), G-CSF, NSC-614629.
Regimen B: Sequential Radiotherapy, Single-Agent Chemotherapy, and Stem Cell Rescue.
Total-body irradiation, TBI (equipment not specified); Etoposide, VP-16, NSC-141540; and
Peripheral Blood Stem Cells, PBSC.
PROJECTED ACCRUAL: 20 patients will be studied.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Thomas R. Klumpp, MD
Fox Chase Cancer Center
United States: Federal Government
|Temple University Cancer Center||Philadelphia, Pennsylvania 19140|